Alloantibody Exchange
A 501(c)(3) Public Charity
OUR MISSION
To enable blood banks to electronically share the transfusion history of their patients.
A winner of the AABB President's Award and the Challenge on Equity from U.S. Department of Health and Human Services Secretary (HHS).
BENEFITS OF ENROLLMENT
Widen your transfusion history search to hospitals across the nation.
Sign in using your hospital credentials. No manual data entry.
Access the test environment
SUPPORTED BY BLOOD BANK CLINICIANS
Join a movement championed by the nation's leading academics. View Letters of Support. (PDF, opens in new tab)
Submision pending...
Submision received.
Submision failed. Is this a valid email?
SUPPORTED BY RESEARCH
Copies available on request.
Positive impact of online inter-hospital consultation of transfusion history on incidence of red cell ABO mistransfusions, acute and delayed hemolytic transfusion reactions
"Rate of ABO incompatibility decreased 4.6-fold, that of AHTR decreased 2-fold and that of DHTR decreased 2.5-fold pre vs post consultation of OLPTH (OnLine the Past Transfusion History, a Quebec-based transfusion history exchange)."
Pierre Robillard, et al.
Enhanced detection of blood bank sample collection errors with a centralized patient database
"Access to a centralized patient database detected 38 percent more ABO typing errors and prevented six mistransfusions, which would not have been prevented at a single institution. Centralization of patient transfusion data should be encouraged."
Duncan MacIvor, et al.
Regional registry of patient alloantibodies: first-year experience
"The regional alloantibody registry prevented potential delayed hemolytic transfusion reactions"
Vicki Schwickerath, et al.
The Canadian transfusion surveillance system: what is it and how can the data be used?
"Since the implementation of this system there has been a significant drop in the frequency of ABO incompatible transfusions, acute hemolytic transfusion reactions and delayed transfusion reactions; hence, safety of the blood system in Québec has been enhanced."
Julie Ditomasso, et al.
The immunohematologic and patient safety benefits of a centralized transfusion database
"The database provides evidence that sharing transfusion information, within regulatory requirements, tangibly improves patient care."
Meghan Delaney, et al.
A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease
“A centralized database can help prevent issuing incompatible RBC units”
Sarah K. Harm, et al.
Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions
"Almost two-thirds of records for patients tested at both hospitals had some form of discrepancy, most commonly the failure of one of the facilities to detect an antibody. Such discrepancies are serious since they constitute risk factors for incompatible transfusions and DHTRs (delayed hemolytic transfusion reactions)."
Nisha Unni, et al.
High Percentage of Evanescent Red Cell Antibodies in Patients with Sickle Cell Disease Highlights Need for a National Antibody Database
“A national or regional alloantibody database should be a priority.”
Lance Williams, et al.
A national Transfusion Register of Irregular Antibodies and Cross (X)-match Problems: TRIX, a 10-year analysis
"Databases for sharing transfusion information between hospitals for enhanced detection of blood type errors and prevention of adverse events are scarce but have a proven positive effect on the prevention of acute and delayed hemolytic transfusions."
Adriaan J. van Gammeren, et al.
TRIX with treats: the considerable safety benefits of a transfusion medicine registry
"A national transfusion medicine registry could prevent DHTRs by sharing alloantibody records between blood banks."
Ronald 'George' Hauser, et al.
Would a National Antibody Register contribute to improving patient outcomes?
"When taken together, the included studies have highlighted and investigated flaws in transfusion services provided around the world, many of which have the potential to be significantly reduced through the introduction of a National registry."
Zachary Powell, et al.
A case for a national registry of red blood cell antibodies
"This case is an example of how a registry of RBC antibodies is critical to providing good patient care."
Gagan Mathur, et al.
Unmasking delayed hemolytic transfusion reactions in patients with sickle-cell disease: Challenges and opportunities for improvement
"We call upon policymakers to consider creating a nationwide database of all SCD patients, regardless of where they have received care. This database should include information on patient blood group genotypes, phenotypes, antibodies, and transfusion histories"
Mischa Covington, et al.
A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease
"By reducing DHTR-specific mortality, an alloantibody exchange is predicted to be a life- and cost-saving investment for alloimmunized people living with SCD."
George Goshua, et al.
Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource
"By reducing DHTR-specific mortality, a shared transfusion resource in the United States projects to be a life-saving and cost-effective intervention for patients with SCD in the United States."
Ito Satoko, et al.
INDUSTRY SUPPORTERS
Partner with us to improve the safety of blood transfusions. Your contribution fuels our adoption. Join the life-saving journey now!
Become our supporter!
Become our supporter!
ENDORSEMENTS
NEXT STEPS FOR CLINICIANS
"We owe it to our patients to provide them a safe blood supply."
John Granton, Alloantibody Exchange petition at Change.org.
-
Add your support to the interactive map.
By completing the form next to the map, it shows you support the Alloantibody Exchange. We can connect you with more supporters in your area with whom you may share patient data with electronically.
-
Implementation begins with a request for more information through this form.
We will meet with you to answer questions. If you want to proceed, we will work toward implementation with you, including providing you with materials to help inform other members of your health system of the Alloantibody Exchange's clinical benefits.
-
Provide a donation.
As a non-profit, donations are critical to our success. The donation link is at the top of the page.
SET UP FOR NON-CLINICIANS
Curious about the setup effort? The process is straightforward.
-
Looking for a security or contracting document?
Beginning at the top of the page, choose 'Get Started' to receive your Project Plan code then login with the 'Project Plan' link.
-
Want to meet?
Click the "Schedule a Meeting" button at the top of the page.
-
Prefer to email?
Find our email here under the "About Us" header.
COMMON QUESTIONS
Sounds great so far, but do you but still have a few questions?
I have concerns about patient data privacy.
Patient data privacy is primary concern for us as well. We will work with your health system IT to perform a security review. This does not involve blood bank staff. It is also helpful to remember the scope of this project only includes information relative to providing appropriately matched blood products. Patients with special transfusion requirements generally make up 1% of a health system’s patient population, and the information collected from this 1% includes only alloantibody, antigen, and special transfusion requirements. We do not collection information on a patient simply because they had a type and screen. We do not collect diagnoses, medications, or billing information. Our focus is very narrow.
I am concerned about HIPAA.
We have read and annotated the HIPAA regulations line-by-line to ensure we comply fully. Read our documentation here (PDF, opens in new tab). Sharing patient information is allowed under HIPAA. It does not require informed consent for the treatment of patients. See HIPAA 165.506(c)(2) on page 84, “A covered entity may disclose PHI for treatment activities of a healthcare provider”. We will work with your health system IT to review HIPAA requirements. This does not involve blood bank staff.
I have concerns about patient identification.
We employ automated procedures developed by a review of health information exchanges to identify patients across systems. We use six patient identifiers: first name, last name, date of birth, birth sex, ABO, and Rh. Although imperfect without a unique national medical identifier, health information exchanges do function successfully in many states. For each patient’s transfusion requirements, we do provide the origin of the information, allowing further dialogue as needed.
I will need to set this up, so please provide me with more details.
Additional details are available on your Project Plan at the top of the page. (Use 'Get Started' to receive a code if you do not have one.) In Project Plan, see the Documents tab. For additional help, click the "Schedule a Meeting" button, also at the top of the page.
More questions and answers here » (PDF, opens in new tab)
CONTACT US
Would you like to learn more?
Submision pending...
Submision received.
Submision failed. Is this a valid email?
ABOUT US
Contact us at 
Ronald George Hauser, MD
President, Founder
Yale University School of Medicine
Neisha Lovett
Director of Communications
Christopher Tormey, MD
Board Member, Founder
Yale University School of Medicine
Stephen Hass
Board Member, Attorney
E. Kevin Hall, MD
Board Member
Yale University School of Medicine
Greg Olsen, MD, MBA
Consultant
University of Florida
Ugo Ugwuowo, MD
Director of Special Projects
Andrew Loza, MD, PhD
Director of Software
Khalda A. Ibrahim, MD
Board Member Emeritus
University of California, Los Angeles